Journal article
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both.
METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. …
Authors
Parving H-H; Brenner BM; McMurray JJV; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M
Journal
The New England Journal of Medicine, Vol. 367, No. 23, pp. 2204–2213
Publisher
Massachusetts Medical Society
Publication Date
December 6, 2012
DOI
10.1056/nejmoa1208799
ISSN
0028-4793
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAmidesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCardiovascular DiseasesDiabetes Mellitus, Type 2Double-Blind MethodDrug Therapy, CombinationFemaleFollow-Up StudiesFumaratesHumansHyperkalemiaHypokalemiaKidney DiseasesMaleMiddle AgedPatient DropoutsReninTreatment Failure